CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis

Annals of Surgical Oncology

Volumn 18, Issue 3, 2011, Pages 857-865

  Dong, Qian Ze ^a   Wang, Yang ^a   Dong, Xin Jun ^a   Li, Zi Xuan ^a   Tang, Zhong Ping ^a   Cui, Quan Ze ^a   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; MESSENGER RNA; MYC PROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; AUTOANTIGENS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 79955739210     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1313-8     Document Type: Article

References (21)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899-909.
2. O'Mahony D, Kummar S, Gutierrez ME. Non-small-cell lung cancer vaccine therapy: A concise review. J Clin Oncol. 2005;23:9022-8. (Pubitemid 46211486)
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-smallcell lung cancer. N Engl J Med. 2005;353:123-32. (Pubitemid 41058344)
4. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-44. (Pubitemid 41058345)
5. Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res. 2006;66:9736-43. (Pubitemid 44623675)
6. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, et al. CIP2A inhibits PP2A in human malignancies. Cell. 2007;130:51-62. (Pubitemid 47039258)
7. Khanna A, Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 2009;101:793-805.
8. Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia J, et al. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res. 2008;14:3722-8.
9. Cǒme C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, et al. CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009;15:5092-100.
10. Burke L, Flieder DB, Guinee DG, Brambilla E, Freedman AN, Bennet WP, et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res. 2005;11:232-41. (Pubitemid 40075800)
11. Arnold HK, Sears RC. A tumor suppressor role for PP2AB56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev. 2008;27:147-58.
12. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle. 2008;7:592-6. (Pubitemid 351498996)
13. Sears RC. The life cycle of C-myc: From synthesis to degradation. Cell Cycle. 2004;3:1133-7. (Pubitemid 40268631)
14. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308-18. (Pubitemid 38584820)
15. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, et al. Function of the c-Myc oncogenic transcription factor. Exp Cell Res. 1999;253:63-77.
16. Volm M, Koomagi R. Prognostic relevance of c-Myc and caspase- 3 for patients with non-small cell lung cancer. Oncol Rep. 2000;7:95-8.
17. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer. 2005;103:1186-94. (Pubitemid 40328089)
18. Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, et al., Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol. 2002;15:35-44. (Pubitemid 34081457)
19. Sharrard RM, Royds JA, Rogers S, Shorthouse AJ. Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br J Cancer. 1992;65:667-72.
20. Watson PH, Safneck JR, Le K, Dubik D, Shiu RP. Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst. 1993;85:902-7. (Pubitemid 23157131)
21. Huang CL, Liu D, Ishikawa S, Nakashima T, Nakashima N, Yokomise H, et al. Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer. 2008;44:2680-8.